11 results about "Postpartum depression" patented technology

The application is suitable for the technical field of artificial intelligence and medical health, and provides a postpartum depression intelligent screening and early intervention system and method, which comprises a whole life cycle management module for managing continuous data flow and state transition; a physical entity layer for collecting physiological data of puerpera, mother-infant behavior interaction data and environmental semantic data; a digital twin layer for constructing a dynamic virtual mapping model, the model comprising a causal graph model based on a structural causal model and a time sequence evolution mechanism; an application service layer for generating and pushing a risk early warning, an attribution analysis and a self-adaptive intervention scheme based on causal reasoning in stages; through causal reasoning instead of correlation analysis, the early warning accuracy is improved, the digital twin layer constructs a puerpera-baby binary group dynamic mapping based on a structural causal model, and through a directed acyclic graph to quantify the causal relationship between variables and combine Monte Carlo tree search to deduce the future risk probability, compared with a traditional scale, high-risk events such as self-harm thoughts can be early warned.

The present application relates to the field of compounds, discloses a kind of steroid compound with general formula I structure and its purposes, preparation method and the pharmaceutical composition comprising the steroid compound, to GABA A Receptor has strong positive regulation, can be used for preparing oral anti-severe depression and postpartum depression drug, with the characteristics of high efficiency.

The invention discloses a postpartum depression risk prediction system and method based on multi-source and multi-scale fusion, and relates to the technical field of data analysis and prediction. The system generates multi-source data records useful for analysis by acquiring short-term dynamic physiological data, long-term stable physiological data, and data related to environmental or behavioral factors at different temporal resolutions. The system performs modeling and scale alignment on the multi-scale features, constructs a potential spatial representation reflecting a multi-modal association relationship, and constructs a cross-modal association structure based on the representation. The system generates a plurality of preliminary risk prediction results through a multi-path or multi-expert model, and fuses the plurality of prediction results according to prediction differences, modal availability and scale buffer features to obtain a unified risk prediction value. And determining a postpartum depression risk level based on the predicted value, and outputting risk assessment information for decision support. According to the invention, fusion processing of multi-source health data can be realized, and prediction support for postpartum depression risk is provided.

The invention relates to the technical field of data processing, in particular to a postpartum depression risk AI dynamic screening method and system. The method comprises the following steps: firstly, analyzing intensity values of different muscles in a user image, and dividing behaviors of a user at different moments into autonomic behaviors and non-autonomic behaviors; the smiling duration and the energy ratio of the autonomic behavior to the non-autonomic behavior are analyzed, an emotion contradiction index is determined, and then a contradictory smiling window is divided; determining a physiological comprehensive value by combining the stress delay angle and the recovery delay angle; analyzing forward control and reverse feedback from emotion to physiology to obtain a bidirectional path coordination ratio; screening out an imbalance event from a contradictory smile window through a bidirectional path coordination ratio; and for the unbalance event, determining the total unbalance risk of the postpartum user in combination with the bidirectional path coordination ratio and the physiological comprehensive value. According to the invention, the accuracy of postpartum depression risk screening is improved.

This invention relates to the field of microbial pharmaceutical technology, specifically disclosing the application of *Blautia Obeum* in the preparation of drugs for the prevention and treatment of depression, representing a novel use of probiotics for antidepressant purposes. This invention is the first to apply *Blautia Obeum* to the prevention and treatment of depression. This strain can be prepared in various forms, including live bacterial preparations, inactivated bacterial cells, bacterial lysates, metabolites, or bacterial extracts, combined with pharmaceutically acceptable excipients to formulate various oral microecological preparations, including conventional dosage forms such as tablets, capsules, enteric-coated preparations, and oral liquids. The drugs can effectively improve core clinical symptoms of depression, such as low mood, loss of interest, sleep disorders, anxiety, and irritability, by regulating intestinal flora homeostasis, repairing intestinal barrier function, and modulating the brain-gut axis signaling pathway. It is suitable for the prevention and treatment of various types of depression, including major depressive disorder, postpartum depression, geriatric depression, and chronic stress-induced depression. The strain used in this invention is safe and highly compatible, and the preparation is convenient to administer, providing a novel microecological intervention scheme for the clinical prevention and treatment of depression, overcoming some limitations of existing antidepressant methods, and possessing good prospects for pharmaceutical development.

The invention provides application of a chalcone compound as well as a stereoisomer, a pharmaceutically acceptable salt or a solvate thereof in preparation of a medicament for treating depression. The depression is selected from mild depression, moderate depression, severe depression, persistent depressive disorder, depression associated with bipolar disorder, seasonal affective disorder, psychotic depression, postpartum depression, premenstrual anxiety disorder, encountering depression, pleasant sensation deficiency, melancholia, middle-year depression and late-year depression; depression caused by identifiable pressure factors, refractory depression, or a combination thereof. The compounds can treat mental symptoms of depression, such as depressive mood and loss of interest or fun in almost all activities.

The invention relates to the technical field of functional food, and particularly discloses medicinal and edible formula powder for regulating postpartum depression and physiological disorder and a preparation method thereof, and the medicinal and edible formula powder comprises the following components in parts by mass: 115-125 parts of black sesame, 8-15 parts of an active extract, 55-65 parts of a tartary buckwheat compound, 55-65 parts of radix puerariae, 46-50 parts of radix rehmanniae, 5-9 parts of Chinese wolfberry and hawthorn polysaccharide, 32-38 parts of chrysanthemum and 45-50 parts of rock candy. The black sesame provides a nutrition basis, and the black sesame, the radix puerariae and the radix rehmanniae regulate postpartum estrogen fluctuation; the active extract and active ingredients in the tartary buckwheat compound form a synergistic effect, oxidative stress products are removed in a linkage manner, the serum MDA level is reduced, and cortisol is regulated; polysaccharide components of the Chinese wolfberry fruits and the hawthorn fruits synergistically improve immunity; the prepared formula powder can effectively improve the physiological function of postpartum people and improve postpartum depression.

The invention relates to an essential oil composition for relieving postpartum melancholia and application thereof. The composition comprises lavender essential oil, sweet orange essential oil, frankincense essential oil, sandalwood essential oil, rosemary essential oil, base oil and auxiliary components. Through the composite effect of various essential oils, the symptoms of the postpartum depression, including anxiety, emotional fluctuation, body pain, inattention and the like, can be comprehensively relieved. The essential oil composition has the advantages of being high in safety, good in comfort, convenient to use and the like, is suitable for lying-in women to use, and can effectively improve the physical and psychological health of the lying-in women and improve the family life quality.

The present invention belongs to the technical field of medicine. Provided are a crystal form of a neuroactive steroid derivative and the use thereof. For the crystal form of the neuroactive steroid derivative (having a structure represented by formula (I)), the characteristic diffraction peaks in an X-ray powder diffraction pattern expressed as 2θ angles using Cu-Kα radiation include 11.450±0.200°, 15.724±0.200°, 19.040±0.200°, 22.955±0.200° and 24.975±0.200°. The crystal form has good flowability, no electrostatic phenomenon, high stability, and almost no hygroscopicity, and remains stable under high temperature, high humidity and light exposure conditions. The crystal form has a strong positive modulatory effect on a GABAA receptor, and has favorable pharmacokinetic properties and a favorable oral absorption rate. Therefore, the crystal form can be applied in the preparation of oral and other dosage forms of drugs with a high efficacy against diseases such as postpartum depression.

Provided are a crystal form of a neuroactive steroid derivative and use thereof, belonging to the field of pharmaceutical technology. The crystal form of the neuroactive steroid derivative (having a structure represented by formula I) provided by the present disclosure has characteristic diffraction peaks expressed as 2θ angles in an X-ray powder diffraction pattern obtained by using Cu-Kα radiation, including 11.450 ± 0.200°, 15.724 ± 0.200°, 19.040 ± 0.200°, 22.955 ± 0.200° and 24.975 ± 0.200°. The crystal form provided by the present disclosure exhibits good flowability, no electrostatic phenomenon, and high stability, and is almost non-hygroscopic, and can remain stable under high temperature, high humidity and light irradiation conditions. The crystal form has a strong positive modulatory effect on GABAA receptors, has good pharmacokinetic properties and oral absorption rate, and thus can be used for preparation of a drug in oral or other dosage forms for efficiently treating diseases such as postpartum depression.

The invention relates to the technical field of medical monitoring, in particular to a postpartum depression monitoring method and system, and the method comprises the steps: obtaining the evaluation data of a puerpera for an online questionnaire; integrating the personal information of the online questionnaire to a database system, and establishing a personal information file; performing preliminary evaluation on the puerpera according to the evaluation data to obtain a questionnaire evaluation result; grading the health state of the puerpera based on the personal information file and the questionnaire evaluation result; for the target puerpera classified as the critical patient, generating a clinical intervention scheme, pushing the clinical intervention scheme to a responsible doctor, and recording inspection and examination reports in the treatment process; providing videos and article propaganda and education contents related to postpartum depression for a target puerpera to access; performing postpartum follow-up on the treated target puerpera to obtain a follow-up result fed back by the intervention effect, performing association analysis on the follow-up result, the questionnaire evaluation data and the clinical intervention scheme, and outputting an optimized intervention strategy; according to the invention, the comprehensiveness and accuracy of postpartum depression monitoring can be improved.